**Medical Guideline Disclaimer**

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflect how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated, GHI HMO Select, ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

**Definition**

Kyprolis (carfilzomib) is a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors.

Kyprolis (carfilzomib) is FDA approved as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. It is also indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

**Length of Authorization**

a. Coverage will be provided for 6 months and may be renewed.

**Dosing Limits**

b. Cap dose at a single dose limit body surface area (BSA) of 2.2m²
Initial Approval Criteria

Kyprolis (carfilzomib) may be considered medically necessary when any of the following criteria is met:

**Indication**

1. **Multiple Myeloma†**

   The member has multiple myeloma and Kyprolis (carfilzomib) is being used as **ONE** of the following:
   - Patient has relapsed or refractory disease who has received one to three lines of therapy:
     - Used in combination with lenalidomide plus dexamethasone OR
     - In combination with dexamethasone OR
     - As a single agent OR
   - In combination with pomalidomide and dexamethasone for members who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy OR
   - In combination with panobinostat in members who have received at least two prior regimens, including bortezomib and an immunomodulatory agent OR
   - Used in combination with lenalidomide and dexamethasone for transplant candidates and non-transplant patients with active multiple myeloma after 6 months following primary chemotherapy with the same regimen.

**Limitations:**

Kyprolis (carfilzomib) is not considered medically necessary when any of the following selection criteria is met:

1. Member has disease progression while taking Kyprolis (carfilzomib).
2. Kyprolis (carfilzomib) exceeds single dose limit BSA of 2.2 m².
3. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature may be deemed as not approvable and therefore not reimbursable.

† FDA Approved Indication

I. **Renewal Criteria**

   Same as initial prior authorization policy criteria.

II. **Dosage/Administration**

<table>
<thead>
<tr>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please refer to Kyprolis package insert</td>
</tr>
</tbody>
</table>
Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9047</td>
<td>Injection, Carfilzomib, 1 mg</td>
</tr>
</tbody>
</table>

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C90.00</td>
<td>Multiple myeloma not having achieved remission</td>
</tr>
<tr>
<td>C90.02</td>
<td>Multiple myeloma in relapse</td>
</tr>
<tr>
<td>C90.20</td>
<td>Extramedullary plasmacytoma not having achieved remission</td>
</tr>
<tr>
<td>C90.22</td>
<td>Extramedullary plasmacytoma in relapse</td>
</tr>
<tr>
<td>C90.30</td>
<td>Solitary plasmacytoma not having achieved remission</td>
</tr>
<tr>
<td>C90.32</td>
<td>Solitary plasmacytoma in relapse</td>
</tr>
</tbody>
</table>

Revision History

10/30/2019 - Under Initial Approval Criteria, added: Patient has relapsed or refractory disease who has received one to three lines of therapy AND Used in combination with lenalidomide plus dexamethasone OR In combination with dexamethasone OR As a single agent.

- Used in combination with lenalidomide and dexamethasone for transplant candidates and non-transplant patients with active multiple myeloma after 6 months following primary chemotherapy with the same regimen.

References